471 related articles for article (PubMed ID: 34809451)
1. A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model.
Strohmeier S; Amanat F; Zhu X; McMahon M; Deming ME; Pasetti MF; Neuzil KM; Wilson IA; Krammer F
mBio; 2021 Dec; 12(6):e0224121. PubMed ID: 34809451
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
3. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
4. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.
Creytens S; Pascha MN; Ballegeer M; Saelens X; de Haan CAM
Front Immunol; 2021; 12():786617. PubMed ID: 34868073
[TBL] [Abstract][Full Text] [Related]
5. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
[TBL] [Abstract][Full Text] [Related]
6. Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.
Broecker F; Zheng A; Suntronwong N; Sun W; Bailey MJ; Krammer F; Palese P
J Virol; 2019 Sep; 93(18):. PubMed ID: 31375573
[TBL] [Abstract][Full Text] [Related]
7. Design of the Recombinant Influenza Neuraminidase Antigen Is Crucial for Its Biochemical Properties and Protective Efficacy.
Gao J; Klenow L; Parsons L; Malik T; Phue JN; Gao Z; Withers SG; Cipollo J; Daniels R; Wan H
J Virol; 2021 Nov; 95(24):e0116021. PubMed ID: 34613807
[TBL] [Abstract][Full Text] [Related]
8. The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017.
Catani JPP; Smet A; Ysenbaert T; Vuylsteke M; Bottu G; Mathys J; Botzki A; Cortes-Garcia G; Strugnell T; Gomila R; Hamberger J; Catalan J; Ustyugova IV; Farrell T; Stegalkina S; Ray S; LaRue L; Saelens X; Vogel TU
Elife; 2024 May; 12():. PubMed ID: 38805550
[TBL] [Abstract][Full Text] [Related]
9. Lactococcus lactis displayed neuraminidase confers cross protective immunity against influenza A viruses in mice.
Lei H; Peng X; Zhao D; Ouyang J; Jiao H; Shu H; Ge X
Virology; 2015 Feb; 476():189-195. PubMed ID: 25546254
[TBL] [Abstract][Full Text] [Related]
10. Broadly Protective CD8
Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
J Virol; 2021 May; 95(12):. PubMed ID: 33827939
[TBL] [Abstract][Full Text] [Related]
11. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.
Bragstad K; Martel CJ; Thomsen JS; Jensen KL; Nielsen LP; Aasted B; Fomsgaard A
Influenza Other Respir Viruses; 2011 Jan; 5(1):13-23. PubMed ID: 21138536
[TBL] [Abstract][Full Text] [Related]
12. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.
Roubidoux EK; Carreño JM; McMahon M; Jiang K; van Bakel H; Wilson P; Krammer F
mBio; 2021 Feb; 12(1):. PubMed ID: 33593972
[TBL] [Abstract][Full Text] [Related]
14. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge.
Wen Z; Ye L; Gao Y; Pan L; Dong K; Bu Z; Compans RW; Yang C
Antiviral Res; 2009 Dec; 84(3):215-24. PubMed ID: 19772876
[TBL] [Abstract][Full Text] [Related]
15. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
Gao J; Couzens L; Burke DF; Wan H; Wilson P; Memoli MJ; Xu X; Harvey R; Wrammert J; Ahmed R; Taubenberger JK; Smith DJ; Fouchier RAM; Eichelberger MC
mBio; 2019 Apr; 10(2):. PubMed ID: 30967460
[TBL] [Abstract][Full Text] [Related]
16. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
[TBL] [Abstract][Full Text] [Related]
17. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.
Wohlbold TJ; Nachbagauer R; Xu H; Tan GS; Hirsh A; Brokstad KA; Cox RJ; Palese P; Krammer F
mBio; 2015 Mar; 6(2):e02556. PubMed ID: 25759506
[TBL] [Abstract][Full Text] [Related]
19. Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals.
Zheng A; Sun W; Xiong X; Freyn AW; Peukes J; Strohmeier S; Nachbagauer R; Briggs JAG; Krammer F; Palese P
J Virol; 2020 Jul; 94(16):. PubMed ID: 32493826
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
